The University of Warwick spin-out company, CryoLogyx, has been awarded £300k from InnovateUK to develop innovate cryopreservation agents with applications in the diagnostic, medicines discovery and cell-based therapy markets.

For commercial enquiries contact Dr James Lapworth, Warwick Innovations, email: j.lapworth@warwick.ac.uk, tel: + 44 (0)2476 575481

Researchers in the UK and the United States have succeeded in ‘fine tuning’ a new thermoplastic biomaterial to enable both the rate at which it degrades in the body and its mechanical properties to be controlled independently.

For commercial enquiries contact Dr James Lapworth, Warwick Innovations, email: j.lapworth@warwick.ac.uk, tel: + 44 (0)2476 575481

NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director.

VIBE has been designed to complement and enhance your research journey. Over the course of five sessions starting November 3^rd, the programme aims to boost both your personal development and the real-world impact of your research. The facilitators have worked tirelessly to ensure that COVID-19 will not stop participants from getting the most engaging and communal experience possible and have designed a fully immersive and collaborative digital workshop.

Find out more here

Application form here

NanoSyrinx, an emerging biotechnology company developing new therapeutic modalities for Cell & Gene editing, announced the closing of a Pre-Seed financing led by M Ventures, the corporate venture capital arm of Merck. BioCity (Nottingham, United Kingdom) and UK Innovation & Science Seed Fund also participated in the financing.

New study published on rapid test for Coronavirus being developed by University of Warwick demonstrates detection using a model virus rather than just proteins. The diagnostic tool will function without any need for training or complex infrastructure, looking like a ‘pregnancy test’. The team are seeking philanthropic or investment partners to develop and take forward this new technology

The Universities of Birmingham and Warwick have created a new spinout company, 4D Medicine Ltd, to commercialise a new class of materials – liquid resins that can be printed into solid 3D scaffolds to help patients recover from major medical procedures more quickly.

The work being done at University of Warwick, in collaboration with Iceni Diagnostics, around developing a new approach to rapid coronavirus diagnostics has been featured on the BBC. On Thursday 25 June, BBC Midlands interviewed Professor Gibson and members of his team - a feature on this can be read on the BBC News web pages. You can also see the news report video here.

Coronavirus diagnostics currently require centralised facilities and collection/distribution of swabs and results are ‘next day’. A new diagnostic tool being developed by the University of Warwick and its partner Iceni Diagnostics may allow on-the-spot detection of Coronavirus infection, without facilities using a simple disposal device.

University of Warwick spin-out Sarissa Biomedical raises £1.2m for new test to diagnose stroke victims